Get the Stockscreener App
7.93
2.28%
-0.185
Scienture Holdings Inc stock is traded at $7.93, with a volume of 21,047.
It is down -2.28% in the last 24 hours and up +12.80% over the past month.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
See More
Previous Close:
$8.115
Open:
$8
24h Volume:
21,047
Relative Volume:
3.01
Market Cap:
$14.79M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-12.08%
1M Performance:
+12.80%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.955
$8.81
1-Week Range:
$7.20
$8.97
52-Week Range:
$6.50
$9.55
Scienture Holdings Inc Stock (SCNX) Company Profile
Name
Scienture Holdings Inc
Sector
Industry
Phone
(800) 261 0281
Address
2420 BRUNELLO TRACE, LUTZ
Scienture Holdings Inc Stock (SCNX) Latest News
Scienture completes preferred stock conversion By Investing.com - Investing.com Australia
Scienture completes preferred stock conversion - Investing.com India
Scienture : Material Event Form 8 K - Marketscreener.com
Scienture Holdings Shares Insight with Investor Presentation - TipRanks
Gajan A. Mahendiran and Amudha Mahendiran acquired Westminster Pharmaceutical LLC from Trxade Group, Inc. for $1.6 million. - Marketscreener.com
Top Premarket Gainers - Marketscreener.com
Scienture Holdings Unveils New Identity Post-Merger - TipRanks
TRxADE Health changes its name to Scienture Holdings - AlphaStreet
Bats Reveal Superior Adaptation to Endure Heart Stress: National Heart Centre Singapore Partners Paratus Sciences Singapore to Accelerate Heart Failure Care - ForexTV.com
Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner - ForexTV.com
TRxADE Health rebrands as Scienture Holdings with new ticker SCNX - Investing.com
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX” - Morningstar
SCNXScienture Holdings, Inc. Latest Stock News & Market Updates - StockTitan
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. - ForexTV.com
Trxade Health announces name change to Scienture Holdings - TipRanks
Guardian Pharmacy seeks to raise up to $108 mil in US IPO - AlphaStreet
Everything you need to know about Zenas BioPharma’s IPO - AlphaStreet
Trxade Group’s Strategic Merger and Rebranding as Scienture Holdings - TipRanks
TRxADE HEALTH completes all-stock merger deal with Scienture - World Pharmaceutical Frontiers
Trxade Health acquires Scienture in all-stock transaction valued at $103M - TipRanks
Envoy Medical is well-positioned to gain market share in hearing implant space: CEO - AlphaStreet
AgEagle’s latest focus is on tailoring products for defense, public safety industries: CEO - AlphaStreet
Everything you need to know about OS Therapies’ upcoming IPO - AlphaStreet
MEDS Earnings: Highlights of Trxade Health’s Q1 2024 financial results - AlphaStreet
TRxADE Health, Inc. Files its Q1 10-Q; Reporting Positive Net Income Due to Asset Sale - StockTitan
Alumis looks to raise $300 million in IPO. Here’s what you need to know - AlphaStreet
Tempus AI gears up for IPO. Here’s everything you need to know - AlphaStreet
Femasys is committed to providing women with revolutionary healthcare products: CEO - AlphaStreet
Trxade Health, Inc. Announces Special Cash Dividend, Payable on or About March 22, 2024 - Marketscreener.com
Trxade Health Inc. (NASDAQ: MEDS) Q4 2023 Research Summary - AlphaStreet
MEDS Earnings: A snapshot of Trxade Health’s Q3 2023 financial results - AlphaStreet
TRxADE: Q3 Earnings Snapshot - Marketscreener.com
Nordic Group makes another acquisition to diversify earnings base - Yahoo Finance
Trxade Health Inc. (NASDAQ: MEDS) Q3 2023 Research Summary - AlphaStreet
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor - AlphaStreet
symbol__ Stock Quote Price and Forecast - CNN
Continued focus on core B2B segment drives new business: Trxade CEO Suren Ajjarapu - AlphaStreet
TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel - AlphaStreet
Earnings: Trxade Health (MEDS) reports 16% rise in FY22 revenue; loss narrows - AlphaStreet
TRxADE HEALTH, Inc. Announces Janet Huffman, the Chief Financial Officer Terminate Her Offer Letter and Transitioned from Chief Financial Officer to Acting Chief Financial Officer - Marketscreener.com
Current initiatives should enable Flux Power to reach profitability: CEO Ron Dutt - AlphaStreet
Trxade Health Inc. (NASDAQ: MEDS) Q4 2022 Research Summary - AlphaStreet
Trxade (MEDS) is increasing the breadth of product offerings: CEO Suren Ajjarapu - AlphaStreet
Trxade CEO Suren Ajjarapu: Will see the impact of GPO program by Q3 next year - AlphaStreet
Trxade Health beats on Q3 revenue estimate - AlphaStreet
IPO News: Here’s what to know when Sera Prognostics goes public this week - AlphaStreet
No concerns on margin side: Trxade (MEDS) CEO Suren Ajjarapu - AlphaStreet
MEDS Stock Price and Chart — NASDAQ:MEDS - TradingView
Trxade Group, Inc. Elects Donald Almeida to Board of Directors - Marketscreener.com
Scienture Holdings Inc Stock (SCNX) Financials Data
There is no financial data for Scienture Holdings Inc (SCNX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.63%
2.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):